Clareo Health | Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control
Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female adults ≥ 40 years, with a diagnosis of chronic obstructive pulmonary disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2005 and:
1. Smoking history of at least 20 pack years
2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) \< 80% and ≥ 30% of the predicted normal value
3. Post-bronchodilator FEV1/FVC (forced volume capacity) \< 70% (Post refers to within 30 minutes after inhalation of 400 μg of salbutamol)
You may not be if
Patients who were hospitalized for a COPD exacerbation in the 6 weeks prior to screening.
Patients who had a respiratory tract infection within 6 weeks prior to screening.
Patients with concomitant pulmonary disease.
Patients with a history of asthma.
Patients with diabetes type I or uncontrolled diabetes type II.
Any patient with lung cancer or a history of lung cancer.
Patients with a history of certain cardiovascular co-morbid conditions.
